Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. Earnings Recaps

NBIX Health Care 3 recaps
Q1 2026 May 6, 2026

Neurocrine Biosciences' shares rose 9.7% after the quarter, driven by better-than-expected revenue growth led by INGREZZA’s continued double-digit expansion and solid execution across the commercial portfolio.

Key takeaways
  • Total Q1 net product sales surpassed $800 million for the first time, marking 44% year-over-year growth.
  • INGREZZA sales grew 20% year-over-year to $657 million, reflecting robust volume growth and record new patient starts; adjusted for a calendar difference, growth was about 11%.
  • CRENESSITY sales reached $153 million, supported by consistent new patient enrollment and favorable reimbursement despite slight co-pay reset pressures.
  • Management reaffirmed full-year INGREZZA guidance of $2.7 billion to $2.8 billion and anticipates providing updates after the first half of 2026.
  • Pipeline development continues with plans for multiple Phase I and II programs in 2026 and key data readouts in 2027, supporting long-term growth prospects.
Full recap
Q3 2025 Oct 29, 2025

Neurocrine Biosciences showcased robust performance in Q3 2025 with net product sales reaching $790 million, driven by strong growth in both INGREZZA and CRENESSITY as the company executes on its strategic initiatives.

Key takeaways
  • Net sales increased 28% year-over-year, with INGREZZA contributing $687 million and CRENESSITY generating $98 million in its early launch phase.
  • Continued investments in expanding the sales force are aligned with projections for significant growth in the tardive dyskinesia market through 2029.
  • The company remains on track for its R&D productivity goals, with advancements in multiple Phase I and Phase II studies within its pipeline.
  • A planned $150 million increase in SG&A expenses for 2026 reflects a commitment to driving growth in both INGREZZA and CRENESSITY.
  • Neurocrine's financial position remains strong with over $2.1 billion in cash, underpinning future investments in innovation and shareholder returns.
Full recap
Q2 2025 Aug 1, 2025

Neurocrine Biosciences reported a robust second quarter in 2025, achieving $682 million in net product sales—a 17% year-over-year increase—highlighted by the strong performance of its new product CRENESSITY alongside continued growth in INGREZZA.

Key takeaways
  • Net product sales reached $682 million, driven by a significant revenue increase from both INGREZZA and the newly launched CRENESSITY, which generated $53 million in its second quarter.
  • INGREZZA sales totaled $624 million, reflecting successful market access initiatives, a record number of new patient starts, and sales force expansion.
  • CRENESSITY is on track to potentially become a commercial blockbuster, with 75% of dispensed prescriptions being reimbursed and favorable feedback from patients and prescribers.
  • Increased guidance for INGREZZA net sales from $2.4 billion to a range of $2.5-$2.55 billion, anticipating double-digit volume growth despite some near-term gross-to-net pressure.
  • Strong cash position of $1.8 billion supports ongoing R&D efforts and strategic investments, positioning Neurocrine for continued operational growth.
Full recap